CN100503605C - 苯并咪唑衍生物及其作为aⅱ受体拮抗剂的用途 - Google Patents

苯并咪唑衍生物及其作为aⅱ受体拮抗剂的用途 Download PDF

Info

Publication number
CN100503605C
CN100503605C CNB2005800130733A CN200580013073A CN100503605C CN 100503605 C CN100503605 C CN 100503605C CN B2005800130733 A CNB2005800130733 A CN B2005800130733A CN 200580013073 A CN200580013073 A CN 200580013073A CN 100503605 C CN100503605 C CN 100503605C
Authority
CN
China
Prior art keywords
compound
methyl
oxo
diseases
drugs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB2005800130733A
Other languages
English (en)
Chinese (zh)
Other versions
CN1946717A (zh
Inventor
黑板孝信
坂本博辉
小岛真身
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Haisen Bio Pharmaceutical Co ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34858222&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN100503605(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of CN1946717A publication Critical patent/CN1946717A/zh
Application granted granted Critical
Publication of CN100503605C publication Critical patent/CN100503605C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyrrole Compounds (AREA)
CNB2005800130733A 2004-02-25 2005-02-23 苯并咪唑衍生物及其作为aⅱ受体拮抗剂的用途 Expired - Lifetime CN100503605C (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP048928/2004 2004-02-25
JP2004048928 2004-02-25
US11/031,057 2005-01-07

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2008101701465A Division CN101381366B (zh) 2004-02-25 2005-02-23 苯并咪唑衍生物及其制药用途

Publications (2)

Publication Number Publication Date
CN1946717A CN1946717A (zh) 2007-04-11
CN100503605C true CN100503605C (zh) 2009-06-24

Family

ID=34858222

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB2005800130733A Expired - Lifetime CN100503605C (zh) 2004-02-25 2005-02-23 苯并咪唑衍生物及其作为aⅱ受体拮抗剂的用途
CN2008101701465A Expired - Lifetime CN101381366B (zh) 2004-02-25 2005-02-23 苯并咪唑衍生物及其制药用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2008101701465A Expired - Lifetime CN101381366B (zh) 2004-02-25 2005-02-23 苯并咪唑衍生物及其制药用途

Country Status (34)

Country Link
US (3) US7157584B2 (cg-RX-API-DMAC10.html)
EP (3) EP2119715B1 (cg-RX-API-DMAC10.html)
JP (2) JP4256852B2 (cg-RX-API-DMAC10.html)
KR (1) KR101080029B1 (cg-RX-API-DMAC10.html)
CN (2) CN100503605C (cg-RX-API-DMAC10.html)
AR (2) AR047972A1 (cg-RX-API-DMAC10.html)
AT (2) ATE370136T1 (cg-RX-API-DMAC10.html)
AU (1) AU2005214271B8 (cg-RX-API-DMAC10.html)
BE (1) BE2012C025I2 (cg-RX-API-DMAC10.html)
BR (2) BR122012009489B8 (cg-RX-API-DMAC10.html)
CA (1) CA2557538C (cg-RX-API-DMAC10.html)
CY (5) CY1107008T1 (cg-RX-API-DMAC10.html)
DE (3) DE602005002030T2 (cg-RX-API-DMAC10.html)
DK (3) DK1857457T3 (cg-RX-API-DMAC10.html)
ES (3) ES2331209T3 (cg-RX-API-DMAC10.html)
FR (1) FR12C0034I2 (cg-RX-API-DMAC10.html)
HR (3) HRP20070510T3 (cg-RX-API-DMAC10.html)
HU (1) HUS1200008I1 (cg-RX-API-DMAC10.html)
IL (1) IL177533A (cg-RX-API-DMAC10.html)
LU (1) LU91962I2 (cg-RX-API-DMAC10.html)
MA (1) MA28478B1 (cg-RX-API-DMAC10.html)
ME (2) ME01643B (cg-RX-API-DMAC10.html)
MY (1) MY142807A (cg-RX-API-DMAC10.html)
NL (1) NL300802I2 (cg-RX-API-DMAC10.html)
NO (2) NO332344B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ549755A (cg-RX-API-DMAC10.html)
PL (3) PL1718641T3 (cg-RX-API-DMAC10.html)
PT (3) PT1718641E (cg-RX-API-DMAC10.html)
RS (3) RS50537B (cg-RX-API-DMAC10.html)
RU (1) RU2369608C2 (cg-RX-API-DMAC10.html)
SI (3) SI1857457T1 (cg-RX-API-DMAC10.html)
TW (1) TWI336702B (cg-RX-API-DMAC10.html)
WO (1) WO2005080384A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200607241B (cg-RX-API-DMAC10.html)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102351853A (zh) * 2011-08-29 2012-02-15 石药集团欧意药业有限公司 一种阿齐沙坦酯化合物、制备方法及其药物组合物
WO2012097697A1 (zh) 2011-01-20 2012-07-26 江苏豪森医药集团有限公司 阿齐沙坦有机胺盐及其制备方法和用途
CN104016974A (zh) * 2014-06-24 2014-09-03 浙江天宇药业股份有限公司 阿齐沙坦酯中间体及其合成方法、阿齐沙坦酯的合成方法
CN104039779A (zh) * 2012-01-14 2014-09-10 广东东阳光药业有限公司 阿齐沙坦酯钾的晶型及其制备方法及其用途
CN104803998A (zh) * 2015-03-26 2015-07-29 晋江市托美汀生物科技有限公司 一种降低杂质含量的方法
CN105237527A (zh) * 2012-09-28 2016-01-13 武汉朗来科技发展有限公司 苯并咪唑衍生物及其制备方法和医药用途
CN105753854A (zh) * 2014-12-16 2016-07-13 重庆朗天制药有限公司 一种阿齐沙坦酯钾盐的新制备方法
CN109071519A (zh) * 2016-01-28 2018-12-21 株式会社德山 阿齐沙坦及其制造方法

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7157584B2 (en) * 2004-02-25 2007-01-02 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use thereof
NZ555334A (en) 2004-12-24 2010-05-28 Spinifex Pharm Pty Ltd Method of treatment or prophylaxis of a neuropathic condition using AT2 receptor antagonist
JP4465469B2 (ja) * 2005-02-21 2010-05-19 国立大学法人佐賀大学 循環器病マーカーとしてのインターロイキン１３
AR055755A1 (es) * 2005-03-30 2007-09-05 Takeda Pharmaceutical Derivado de bencimidazol, procesos de obtencion, composiciones farmaceuticas y usos.
WO2007097452A1 (ja) * 2006-02-27 2007-08-30 Takeda Pharmaceutical Company Limited 医薬用ブリスターパッケージ
WO2007097451A1 (ja) * 2006-02-27 2007-08-30 Takeda Pharmaceutical Company Limited 医薬パッケージ
JP5230595B2 (ja) * 2006-03-20 2013-07-10 スピニフェクス ファーマシューティカルズ ピーティーワイ リミテッド 炎症性疼痛の治療または予防の方法
EP2068812B9 (en) * 2006-09-25 2012-08-08 Takeda Pharmaceutical Company Limited Medicinal package
TWI415634B (zh) * 2007-03-28 2013-11-21 Takeda Pharmaceutical 固態醫藥組成物
JP2009062296A (ja) * 2007-09-05 2009-03-26 Fujifilm Corp カルボン酸エステル化合物の製造方法
ES2510866T3 (es) * 2008-03-13 2014-10-21 Daiichi Sankyo Company, Limited Mejora de la solubilidad de una preparación que contiene olmesartán medoxomilo
US9169238B2 (en) 2008-07-31 2015-10-27 Takeda Pharmaceutical Company Limited Solid pharmaceutical composition
TW201014850A (en) 2008-09-25 2010-04-16 Takeda Pharmaceutical Solid pharmaceutical composition
US8410284B2 (en) * 2008-10-22 2013-04-02 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2010075347A2 (en) 2008-12-23 2010-07-01 Takeda Pharmaceutical Company Limited Methods of treating hypertension with at least one angiotensin ii receptor blocker and chlorthalidone
US20110009347A1 (en) * 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
NZ703128A (en) 2010-05-11 2016-04-29 Janssen Pharmaceutica Nv Pharmaceutical formulations comprising 1 - (beta-d-glucopyranosyl) - 2 -thienylmethylbenzene derivatives as inhibitors of sglt
WO2012090043A1 (en) 2010-12-29 2012-07-05 Jubilant Life Sciences Limited Novel solid state forms of azilsartan medoxomil and preparation thereof
WO2012107814A1 (en) 2011-02-08 2012-08-16 Jubilant Life Sciences Limited An improved process for the preparation of azilsartan medoxomil
CN102138899B (zh) * 2011-03-18 2013-08-21 海南本创医药科技有限公司 阿齐沙坦酯脂质体固体制剂
WO2012140120A1 (en) 2011-04-13 2012-10-18 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of sglt2
CN102827153B (zh) * 2011-06-14 2016-10-05 江苏豪森药业集团有限公司 阿齐沙坦的晶型及其制备方法
WO2013042067A1 (en) 2011-09-20 2013-03-28 Ranbaxy Laboratories Limited Process for the preparation of potassium salt of azilsartan medoxomil
WO2013042066A1 (en) 2011-09-20 2013-03-28 Ranbaxy Laboratories Limited Process for the preparation of azilsartan medoxomil
BR112014014527A2 (pt) 2011-12-15 2017-06-13 Takeda Pharmaceuticals Usa Inc combinações de azilsartan e clorotalidona para tratar hipertensão em pacientes negros
WO2013088384A2 (en) 2011-12-15 2013-06-20 Jubilant Life Sciences Limited Solid state forms of azilsartan and azilsartan medoxomil monopotassium and preparation thereof
IN2014DN06964A (cg-RX-API-DMAC10.html) * 2012-02-02 2015-04-10 Ranbaxy Lab Ltd
WO2013124748A1 (en) * 2012-02-20 2013-08-29 Alembic Pharmaceuticals Limited Novel polymorphs of azilsartan medoxomil potassium
CZ2012274A3 (cs) * 2012-04-19 2013-10-30 Zentiva, K.S. Zpusob prípravy vysoce cisté draselné soli azilsartanu medoxomilu
WO2013186792A2 (en) * 2012-06-11 2013-12-19 Msn Laboratories Limited Process for the preparation of (5-methyl-2-oxo-l,3-dioxoi-4-vl)methvl 2- ethoxv-l-{[2'-(5-oxo-4,5-dihvdro-l,2,4-oxadiazol-3-vl)biphenyi-4-vl]methyl}- lh-benzimidazole-7-carboxyiate and its salts
US20150291574A1 (en) * 2012-07-09 2015-10-15 Bandi Parthasaradhi Reddy Novel polymorphs of azilsartan
WO2014020381A1 (en) * 2012-08-01 2014-02-06 Alembic Pharmaceuticals Limited Novel crystalline form of azilsartan medoxomil potassium
EP2925753A4 (en) 2012-08-27 2017-02-15 Hetero Research Foundation Novel polymorphs of azilsartan medoxomil
CZ305318B6 (cs) * 2012-09-26 2015-07-29 Zentiva, K.S. Způsob přípravy vysoce čisté draselné soli azilsartanu medoxomilu
WO2014049512A2 (en) 2012-09-26 2014-04-03 Lupin Limited Novel process for preparation of azilsartan medoxomil
IN2015DN03055A (cg-RX-API-DMAC10.html) * 2012-10-09 2015-10-02 Avery Dennison Corp
CN103910720A (zh) * 2013-01-07 2014-07-09 广东东阳光药业有限公司 阿齐沙坦酯的新晶型及其制备方法
CN105153141B (zh) * 2013-02-04 2018-09-25 武汉朗来科技发展有限公司 苯并咪唑衍生物及其制备方法和医药用途
JP6281735B2 (ja) * 2013-03-19 2018-02-21 トーアエイヨー株式会社 急性心不全治療薬の評価方法、及び、急性心不全モデルの作製方法
RU2535004C1 (ru) * 2013-06-11 2014-12-10 Николай Андреевич Козлов Способ лечения грыж межпозвонковых дисков у собак
RU2535005C1 (ru) * 2013-06-11 2014-12-10 Николай Андреевич Козлов Способ лечения грыж межпозвонковых дисков у собак
CN105949182B (zh) * 2013-10-12 2019-03-19 杭州领业医药科技有限公司 阿齐沙坦酯的晶型及其制备方法
CN104812752B (zh) * 2013-10-12 2016-09-28 杭州领业医药科技有限公司 阿齐沙坦酯的晶型及其制备方法
CN104774196B (zh) * 2014-01-09 2017-11-10 武汉朗来科技发展有限公司 一种苯并咪唑衍生物的制备方法
CN104774197B (zh) * 2014-01-09 2017-11-17 武汉朗来科技发展有限公司 一种苯并咪唑衍生物的制备方法
CN105079815A (zh) * 2014-04-30 2015-11-25 广东东阳光药业有限公司 一种阿齐沙坦酯钾组合物及其制备方法
CZ2014702A3 (cs) 2014-10-15 2016-04-27 Zentiva, K.S. Způsob přípravy vysoce čistého azilsartanu
CN105622595A (zh) * 2014-11-21 2016-06-01 重庆朗天制药有限公司 一种阿奇沙坦酯钾盐及其中间体新的制备方法
US9708306B2 (en) 2015-03-18 2017-07-18 Wuhan Ll Science And Technology Development Co., Ltd Benzimidazole derivatives and preparation process and pharmaceutical uses thereof
CN106032378B (zh) * 2015-03-20 2019-10-25 武汉启瑞药业有限公司 新型arb化合物及其用途
WO2017017165A1 (en) * 2015-07-29 2017-02-02 Takeda Gmbh Pde4 inhibitor for the treatment of diabetic nephropathy
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
JP6856365B2 (ja) * 2016-11-30 2021-04-07 株式会社トクヤマ アジルサルタンの製造方法
CN105628824B (zh) * 2016-03-06 2017-10-17 江苏正大清江制药有限公司 一种高效液相色谱法测定阿齐沙坦原料中有关物质的方法
CN107400122B (zh) * 2016-05-20 2020-10-23 武汉朗来科技发展有限公司 化合物及其制备方法、组合物和应用
CN105770876B (zh) * 2016-05-30 2019-09-10 广东天普生化医药股份有限公司 乌司他丁在制备治疗慢性前列腺炎药物中的用途
WO2018010622A1 (zh) * 2016-07-11 2018-01-18 武汉朗来科技发展有限公司 化合物的晶型及其制备方法、组合物和应用
RU2623082C1 (ru) * 2016-07-11 2017-06-21 Государственное бюджетное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ коррекции артериальной ригидности у больных ревматоидным артритом
CN106074416A (zh) * 2016-08-30 2016-11-09 佛山市弘泰药物研发有限公司 一种阿齐沙坦酯钾盐分散片的制备方法
US11096928B2 (en) * 2016-10-08 2021-08-24 Wuhan Ll Science And Technology Development Co., Ltd. Pharmaceutical composition
IN201721047406A (cg-RX-API-DMAC10.html) 2017-12-30 2020-06-19 Lupin Limited
CN110237071B (zh) * 2018-03-09 2022-03-22 武汉朗来科技发展有限公司 药物制剂及其应用
CN110237072B (zh) * 2018-03-09 2022-03-25 武汉朗来科技发展有限公司 药物组合物的制备方法
CN112955965B (zh) * 2018-06-14 2024-04-09 阿斯利康(英国)有限公司 使用二氢吡啶类钙通道阻断剂医药组合物降低血压的方法
CA3103599A1 (en) 2018-06-14 2019-12-19 Astrazeneca Uk Limited Methods for treatment of hypertension with an angiotensin ii receptor blocker pharmaceutical composition
KR20200057662A (ko) 2018-11-16 2020-05-26 엠에프씨 주식회사 아질사르탄 유도체 화합물, 이의 중간체, 이의 제조방법 및 이를 포함하는 조성물
WO2020166710A1 (ja) * 2019-02-15 2020-08-20 国立大学法人東北大学 １，３－ジオキソラン誘導体
KR102220011B1 (ko) 2020-05-15 2021-02-25 대봉엘에스 주식회사 친환경 용매를 이용한 아질사탄의 제조방법 및 이에 관한 핵심 중간체 화합물
CN115197205A (zh) * 2021-04-08 2022-10-18 广东东阳光药业有限公司 一种盐的晶型及其制备方法
CN113912580B (zh) * 2021-11-03 2023-06-02 瑞孚信江苏药业股份有限公司 一种纯化4-(羟甲基)-5-甲基-[1,3]二氧杂环戊烯-2-酮的方法
WO2023127853A1 (ja) 2021-12-28 2023-07-06 株式会社アークメディスン 化合物、アンジオテンシンｉｉタイプ１受容体拮抗剤及び医薬組成物
KR102862852B1 (ko) 2022-09-19 2025-09-22 대봉엘에스 주식회사 안지오텐신 ⅱ 길항제로서의 아질사르탄 디시클로헥실아민 및 이를 유효성분으로 하는 심혈관질환 치료 또는 예방용 약학적 조성물
US20260191830A1 (en) * 2022-11-24 2026-07-09 Shanghai Aurora Biotechnology Co., Ltd. Pharmaceutical composition comprising azilsartan medoxomil potassium and calcium channel blocker, method for preparing same, and use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0520423A2 (en) * 1991-06-27 1992-12-30 Takeda Chemical Industries, Ltd. Heterocyclic compounds, their production and use as angiotensin II antagonists
WO2003047573A1 (en) * 2001-12-03 2003-06-12 Takeda Chemical Industries, Ltd. Insulin resistance improving agents

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62290071A (ja) 1986-06-09 1987-12-16 Matsushita Electric Ind Co Ltd 有機電解質二次電池
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
CA2229000C (en) 1991-02-21 2002-04-09 Sankyo Company, Limited 1-biphenylimidazole derivatives, their preparation and their therapeutic use
US5616599A (en) 1991-02-21 1997-04-01 Sankyo Company, Limited Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
US5310929A (en) 1992-08-06 1994-05-10 E. I. Du Pont De Nemours And Company Prodrugs of imidazole carboxylic acids as angiotensin II receptor antagonists
US5605919A (en) * 1993-02-26 1997-02-25 Takeda Chemical Industries, Ltd. Treatment for viral diseases
FR2708612B1 (fr) * 1993-08-05 1996-03-01 Roussel Uclaf Nouveaux dérivés bicycliques de l'imidazole, leur procédé de préparation, les nouveaux intermédiaires obtenus, leur application à titre de médicaments et les compositions pharmaceutiques les renfermant.
US5610314A (en) 1995-04-03 1997-03-11 Bristol-Myers Squibb Company Process for preparing dioxolenone derivatives used for making prodrug esters and intermediates
US6974806B2 (en) 2000-07-13 2005-12-13 Takeda Pharmaceutical Company Limited Lipid-rich plaque inhibitors
KR20040081123A (ko) 2002-01-11 2004-09-20 다케다 야쿠힌 고교 가부시키가이샤 쿠마린 유도체, 이의 제조 방법 및 용도
US20070004736A1 (en) 2002-11-22 2007-01-04 Keiji Kubo Imidazole derivative, process for producing the same, and use
US6972258B2 (en) * 2003-08-04 2005-12-06 Taiwan Semiconductor Manufacturing Co., Ltd. Method for selectively controlling damascene CD bias
US7157584B2 (en) * 2004-02-25 2007-01-02 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use thereof
JP4364171B2 (ja) 2005-07-15 2009-11-11 本田技研工業株式会社 自動車用ドアチェッカ

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0520423A2 (en) * 1991-06-27 1992-12-30 Takeda Chemical Industries, Ltd. Heterocyclic compounds, their production and use as angiotensin II antagonists
WO2003047573A1 (en) * 2001-12-03 2003-06-12 Takeda Chemical Industries, Ltd. Insulin resistance improving agents
EP1452176A1 (en) * 2001-12-03 2004-09-01 Takeda Chemical Industries, Ltd. Insulin resistance improving agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Nonpeptide angiotensin receptor antagonists.Synthesisand biological activity of benzimidazoles. KUBO ET AL.JOURNAL OF MEDICINAL CHEMISTRY,Vol.36 No.12. 1993 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012097697A1 (zh) 2011-01-20 2012-07-26 江苏豪森医药集团有限公司 阿齐沙坦有机胺盐及其制备方法和用途
US9233954B2 (en) 2011-01-20 2016-01-12 Jiangsu Hansoh Pharmaceutical Co., Ltd. Organic amine salts of Azilsartan, preparation method and use thereof
CN102351853A (zh) * 2011-08-29 2012-02-15 石药集团欧意药业有限公司 一种阿齐沙坦酯化合物、制备方法及其药物组合物
CN102351853B (zh) * 2011-08-29 2014-03-12 石药集团欧意药业有限公司 一种阿齐沙坦酯化合物、制备方法及其药物组合物
CN104039779A (zh) * 2012-01-14 2014-09-10 广东东阳光药业有限公司 阿齐沙坦酯钾的晶型及其制备方法及其用途
CN104039779B (zh) * 2012-01-14 2016-08-24 广东东阳光药业有限公司 阿齐沙坦酯钾的晶型及其制备方法及其用途
CN105237527A (zh) * 2012-09-28 2016-01-13 武汉朗来科技发展有限公司 苯并咪唑衍生物及其制备方法和医药用途
CN104016974A (zh) * 2014-06-24 2014-09-03 浙江天宇药业股份有限公司 阿齐沙坦酯中间体及其合成方法、阿齐沙坦酯的合成方法
CN105753854A (zh) * 2014-12-16 2016-07-13 重庆朗天制药有限公司 一种阿齐沙坦酯钾盐的新制备方法
CN104803998A (zh) * 2015-03-26 2015-07-29 晋江市托美汀生物科技有限公司 一种降低杂质含量的方法
CN104803998B (zh) * 2015-03-26 2017-08-25 晋江市托美汀生物科技有限公司 一种降低杂质含量的方法
CN109071519A (zh) * 2016-01-28 2018-12-21 株式会社德山 阿齐沙坦及其制造方法

Also Published As

Publication number Publication date
RU2501798C2 (ru) 2013-12-20
LU91962I2 (fr) 2012-05-21
CY1113084T1 (el) 2016-04-13
DK1857457T3 (da) 2009-12-21
JP4256852B2 (ja) 2009-04-22
FR12C0034I2 (fr) 2013-01-11
MA28478B1 (fr) 2007-03-01
NO20064251L (no) 2006-11-22
CY2012015I1 (el) 2016-12-14
DE602005016162D1 (de) 2009-10-01
RS52376B (sr) 2012-12-31
US20060281795A1 (en) 2006-12-14
PL1718641T3 (pl) 2008-01-31
CN1946717A (zh) 2007-04-11
ES2331209T3 (es) 2009-12-23
NL300802I2 (cg-RX-API-DMAC10.html) 2016-05-18
NO2012017I1 (no) 2012-11-26
ME01643B (me) 2010-05-07
ATE370136T1 (de) 2007-09-15
TW200530227A (en) 2005-09-16
CY2012015I2 (el) 2016-12-14
EP2119715B1 (en) 2012-05-30
RS51137B (sr) 2010-10-31
EP1718641A2 (en) 2006-11-08
NO2012017I2 (no) 2012-11-09
EP2119715A1 (en) 2009-11-18
CY2012016I2 (el) 2016-12-14
EP1857457B1 (en) 2009-08-19
BE2012C025I2 (cg-RX-API-DMAC10.html) 2024-08-08
JP2005272451A (ja) 2005-10-06
ES2293552T3 (es) 2008-03-16
BRPI0507984B1 (pt) 2018-07-03
HUS1200008I1 (hu) 2017-06-28
RU2369608C2 (ru) 2009-10-10
CY1107008T1 (el) 2012-09-26
BRPI0507984A (pt) 2007-07-24
RU2006133898A (ru) 2008-03-27
DE602005002030D1 (de) 2007-09-27
EP1857457A2 (en) 2007-11-21
ME01089B (me) 2013-03-20
CA2557538A1 (en) 2005-09-01
ES2388945T3 (es) 2012-10-22
DK1718641T3 (da) 2007-12-17
KR20070020411A (ko) 2007-02-21
SI1718641T1 (sl) 2007-12-31
HRP20090593T1 (hr) 2010-03-31
FR12C0034I1 (fr) 2012-06-15
HRP20070510T3 (hr) 2007-12-31
US7572920B2 (en) 2009-08-11
PT1857457E (pt) 2009-09-23
AU2005214271A2 (en) 2005-09-01
US20050187269A1 (en) 2005-08-25
TWI336702B (en) 2011-02-01
CY2012016I1 (el) 2016-12-14
RS50537B (sr) 2010-05-07
EP1718641B1 (en) 2007-08-15
IL177533A0 (en) 2006-12-10
US7875637B2 (en) 2011-01-25
US20090270464A1 (en) 2009-10-29
BR122012009489B8 (pt) 2023-03-21
SI1857457T1 (sl) 2010-01-29
WO2005080384A2 (en) 2005-09-01
PL1857457T3 (pl) 2009-12-31
NZ549755A (en) 2009-04-30
AU2005214271A1 (en) 2005-09-01
BRPI0507984B8 (pt) 2023-03-21
PT2119715E (pt) 2012-09-03
DE122012000018I1 (de) 2012-06-06
EP1857457A3 (en) 2007-12-05
SI2119715T1 (sl) 2012-10-30
AU2005214271B2 (en) 2011-02-24
JP2009137974A (ja) 2009-06-25
DK2119715T3 (da) 2012-09-10
WO2005080384A3 (en) 2006-09-28
ATE440095T1 (de) 2009-09-15
RU2009115498A (ru) 2010-10-27
US7157584B2 (en) 2007-01-02
HK1115118A1 (en) 2008-11-21
AR047972A1 (es) 2006-03-15
CA2557538C (en) 2010-08-17
PL2119715T3 (pl) 2012-10-31
IL177533A (en) 2010-12-30
CN101381366A (zh) 2009-03-11
HRP20120667T1 (en) 2012-09-30
AR094588A2 (es) 2015-08-12
NO332344B1 (no) 2012-09-03
HK1098472A1 (en) 2007-07-20
HRP20120667T2 (hr) 2012-11-30
CN101381366B (zh) 2011-06-15
MY142807A (en) 2011-01-14
PT1718641E (pt) 2007-11-15
DE602005002030T2 (de) 2008-05-08
BR122012009489B1 (pt) 2019-02-19
WO2005080384A9 (en) 2006-11-30
AU2005214271B8 (en) 2011-03-03
CY1109610T1 (el) 2014-08-13
KR101080029B1 (ko) 2011-11-04
ZA200607241B (en) 2008-04-30

Similar Documents

Publication Publication Date Title
CN101381366B (zh) 苯并咪唑衍生物及其制药用途
RU2407742C2 (ru) Производное бензимидазола и применение в качестве антагониста ангиотензина ii
CN101151260B (zh) 苯并咪唑衍生物及其作为血管紧张素ⅱ拮抗剂的用途
HK1115118B (en) Benzimidazole derivative and its use as aii receptor antagonist
MXPA06009260A (es) Derivado de bencimidazol y uso del mismo
HK1098472B (en) Benzimidazole derivative and its use as a ii receptor antagonist

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20220928

Address after: Building 17, No. 1, Linhe Science and Technology Innovation Town, Mayor of Hefei, Anhui Province

Patentee after: Haisen Bio-Pharmaceutical Co.,Ltd.

Address before: Osaka, Japan

Patentee before: TAKEDA PHARMACEUTICAL Co.,Ltd.

TR01 Transfer of patent right
DD01 Delivery of document by public notice

Addressee: Cao Xueqin

Document name: Decision on Examination of Invalidation Request

DD01 Delivery of document by public notice
CX01 Expiry of patent term

Granted publication date: 20090624

CX01 Expiry of patent term